Advertisement
Screener

Viridian Therapeutics, Inc./DE (VRDN) Graph

VRDN Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue (m); Revenue including tax $284.00K; Cost of revenue (m); Research and development (m).
  • 2026-03-31: Revenue (m); Revenue including tax $141.00K; Cost of revenue (m); Research and development (m).
  • 2025-12-31: Revenue (m); Revenue including tax $132.00K*; Cost of revenue (m); Research and development (m).
  • 2025-09-30: Revenue (m); Revenue including tax $70.57M; Cost of revenue (m); Research and development (m).

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

VRDN revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.License$233.00KRevenue$284.00KOperating expenses$126.55MOperating income-$126.27MSelling, general& administrative$54.98MNet income-$127.12M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30(m)$284.00K(m)(m)$54.98M$126.55M-$127.12M
2026-03-31(m)$141.00K(m)(m)$38.68M$116.31M-$104.90M
2025-12-31(m)$132.00K*(m)(m)(m)$122.88M*-$120.35M*
2025-09-30(m)$70.57M(m)(m)(m)$110.58M-$34.60M
2025-06-30(m)$75.00K(m)(m)$20.22M$106.84M-$100.73M
2025-03-31(m)$72.00K(m)(m)$17.10M$93.94M-$86.91M
2024-09-30(m)$86.00K(m)(m)(m)$83.57M-$76.69M
2024-06-30(m)$72.00K(m)(m)(m)$72.26M-$64.99M
2024-03-31(m)$72.00K(m)(m)(m)$55.97M-$48.54M
2023-09-30(m)$72.00K(m)(m)(m)$51.30M-$47.66M
2023-06-30(m)$72.00K(m)(m)(m)$59.35M-$55.06M
2023-03-31(m)$98.00K(m)(m)(m)$72.57M-$68.15M
2022-09-30(m)$1.20M(m)(m)(m)$30.98M-$28.91M
2022-06-30(m)$256.00K(m)(m)(m)$29.82M-$29.49M
2022-03-31(m)$216.00K(m)(m)(m)$26.11M-$25.69M
2021-09-30(m)$208.00K(m)(m)(m)$14.34M-$14.04M
2021-06-30(m)$1.09M(m)(m)(m)$19.09M-$17.96M
2021-03-31(m)$1.45M(m)(m)(m)$19.97M-$18.46M
2020-09-30(m)$0.00(m)$3.11M(m)$5.41M-$5.49M
2020-06-30(m)$168.00K(m)$3.84M(m)$6.54M-$6.43M
2020-03-31(m)$828.00K(m)$6.10M(m)$8.83M-$8.04M
2019-12-31(m)$880.00K(m)$8.42M(m)(m)-$10.12M
2019-09-30(m)$695.00K(m)$9.03M(m)$11.93M-$11.23M
2019-06-30(m)$2.51M(m)$8.60M(m)$11.46M-$8.90M
2019-03-31(m)$372.00K(m)$8.75M(m)$12.11M-$11.63M
2018-12-31(m)$476.00K(m)$8.23M(m)(m)-$10.32M
2018-09-30(m)$944.00K(m)$7.40M(m)$10.10M-$9.01M
2018-06-30(m)$2.18M(m)$8.38M(m)$11.04M-$8.71M
2018-03-31$4.78M$4.78M(m)$6.41M(m)$9.40M-$4.66M
2017-12-31$1.19M$1.19M(m)$5.00M(m)(m)-$6.39M
2017-09-30$1.63M$1.63M(m)$5.02M(m)$7.52M-$5.83M
2017-06-30$718.00K$718.00K(m)$5.49M(m)$8.07M-$7.31M
2017-03-31$462.00K$462.00K(m)$4.12M(m)$7.40M-$6.98M
2016-12-31$509.00K(m)$692.00K*$3.91M(m)(m)-$5.97M
2016-09-30$936.00K(m)$599.00K$2.96M(m)$5.02M-$4.15M
2016-06-30$1.11M(m)$628.00K$3.35M(m)$4.57M-$3.52M
2016-03-31$917.00K(m)$629.00K$3.47M(m)$4.46M-$3.62M
2015-12-31(m)(m)(m)(m)(m)$3.62M*(m)
2015-09-30$501.00K(m)$577.00K$253.00K(m)$3.63M-$3.15M
2015-06-30(m)(m)$678.00K$194.00K(m)$3.22M-$2.56M
2015-03-31(m)(m)$760.00K$100.00K(m)$3.26M-$2.63M
2014-09-30(m)(m)$900.00K$105.00K(m)$2.93M-$1.64M
2014-06-30(m)(m)$954.00K$128.00K(m)$4.08M-$3.29M
2014-03-31(m)(m)$731.00K$35.00K(m)$1.26M-$706.00K
2013-09-30(m)(m)$713.20K$46.60K(m)$1.30M-$939.63K
2013-06-30(m)(m)$603.05K$22.82K(m)$1.16M-$629.69K

Revenue and expense 6 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30(m)$425.00K(m)(m)$93.65M$242.86M-$232.02M
2025-06-30(m)$147.00K(m)(m)$37.32M$200.78M-$187.65M
2024-06-30(m)$144.00K(m)(m)(m)$128.23M-$113.53M
2023-06-30(m)$170.00K(m)(m)(m)$131.92M-$123.21M
2022-06-30(m)$472.00K(m)(m)(m)$55.92M-$55.18M
2021-06-30(m)$2.54M(m)(m)(m)$39.05M-$36.42M
2020-06-30(m)$996.00K(m)$9.94M(m)$15.37M-$14.48M
2019-06-30(m)$2.89M(m)$17.35M(m)$23.56M-$20.52M
2018-06-30(m)$6.97M(m)$14.79M(m)$20.45M-$13.38M
2017-06-30$1.18M$1.18M(m)$9.61M(m)$15.47M-$14.29M
2016-06-30$2.03M(m)$1.26M$6.82M(m)$9.02M-$7.15M
2015-06-30(m)(m)$1.44M$293.00K(m)$6.48M-$5.20M
2014-06-30(m)(m)$1.69M$162.00K(m)$5.34M-$4.00M
2013-06-30(m)(m)$1.27M$68.56K(m)$2.38M-$1.26M

Revenue and expense 9 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesNet income
2025-09-30(m)$70.72M(m)(m)$311.36M-$222.25M
2024-09-30(m)$230.00K(m)(m)$211.79M-$190.22M
2023-09-30(m)$242.00K(m)(m)$183.21M-$170.87M
2022-09-30(m)$1.67M(m)(m)$86.91M-$84.09M
2021-09-30(m)$2.75M(m)(m)$53.40M-$50.47M
2020-09-30(m)$996.00K(m)$13.05M$20.78M-$19.97M
2019-09-30(m)$3.58M(m)$26.38M$35.49M-$31.75M
2018-09-30(m)$7.91M(m)$22.19M$30.54M-$22.39M
2017-09-30$2.81M$2.81M(m)$14.63M$22.99M-$20.13M
2016-09-30$2.97M(m)$1.86M$9.79M$14.04M-$11.30M
2015-09-30$1.88M(m)$2.02M$546.00K$10.11M-$8.35M
2014-09-30(m)(m)$2.58M$267.00K$8.28M-$5.63M
2013-09-30(m)(m)$2.11M$182.19K$3.68M-$2.20M

Revenue and expense 12 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31(m)$70.85M(m)(m)$95.31M$434.24M$0.00-$342.60M
2024-12-31(m)$302.00K(m)(m)$61.08M$299.34M(m)-$269.90M
2023-12-31(m)$314.00K(m)(m)$95.00M$254.76M(m)-$237.70M
2022-12-31(m)$1.77M(m)(m)(m)$136.08M(m)-$129.90M
2021-12-31(m)$2.96M(m)(m)(m)$82.69M(m)-$79.40M
2020-12-31(m)$1.05M(m)(m)(m)$111.43M(m)-$110.72M
2019-12-31(m)$4.46M(m)$34.79M(m)$46.44M(m)-$41.87M
2018-12-31(m)$8.39M(m)$30.42M(m)$41.47M(m)-$32.70M
2017-12-31$4.00M$4.00M(m)$19.62M(m)$30.54M(m)-$26.51M
2016-12-31$3.48M(m)$2.55M$13.69M(m)$20.46M(m)-$17.27M
2015-12-31$2.54M(m)$2.47M$1.00M(m)$13.72M$0.00-$11.33M
2014-12-31(m)(m)$3.37M$347.00K(m)$11.19M$0.00-$7.89M
2013-12-31(m)(m)$2.78M$225.00K(m)$4.51M(m)-$2.16M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
uniQure N.V. (QURE)$2.416B-4.93
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
Zai Lab Ltd (ZLAB)$2.241B-113.34
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03